Overview
ARWR market data
Price History
ARWR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.01 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.30 – $95.49 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $13K · P/B 10.04 · P/S 20.90.
Company news
Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120Benzinga · Jul 23, 2026, 6:00 PM
Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126Benzinga · Jul 23, 2026, 2:12 PM
Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115Benzinga · Jul 22, 2026, 7:23 PM
Arrowhead Drug Shows Strong Efficacy In Cutting Blood FatBenzinga · Jul 22, 2026, 6:25 PM
Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88Benzinga · Jul 22, 2026, 4:58 PM
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 EarningsBenzinga · Jul 22, 2026, 4:09 PM
CME Group, Weatherford International, RPM International And Other Big Stocks Moving Higher On WednesdayBenzinga · Jul 22, 2026, 2:04 PM
Arrowhead Pharmaceuticals shares are trading higher after the company announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies met their primary and secondary endpoints.Benzinga · Jul 22, 2026, 11:41 AM
Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From BaselineBenzinga · Jul 22, 2026, 11:32 AM
Arrowhead Pharmaceuticals shares are trading higher after JP Morgan raised its price target on the stock from $88 to $95.Benzinga · Jul 17, 2026, 7:51 PM